Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Canadians with hemophilia A can use new treatment option, XYNTHA

Canadians with hemophilia A - a rare, inherited blood-clotting disorder - now have a new treatment option with the introduction of XYNTHA(TM), a recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis.

2 Dec 2009

MRI pioneer honored with MRC Millennium Medal

Sir Peter Mansfield, The University of Nottingham's Nobel Laureate for Physiology and Medicine, is to be recognised, once again, for his part in one of the most important breakthroughs in medical science.

2 Dec 2009

FDA grants approval for Dyax' KALBITOR for treating HAE patients

Dyax Corp. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

2 Dec 2009

Missouri scientists discover aspirin and Tylenol can inhibit vaccine efficacy

With flu season in full swing and the threat of H1N1 looming, demand for vaccines is at an all-time high. Although those vaccines are expected to be effective, University of Missouri researchers have found further evidence that some over-the-counter drugs, such as aspirin and Tylenol, that inhibit certain enzymes could impact the effectiveness of vaccines.

1 Dec 2009

MedImmune to develop and commercialize Trellis Bioscience's anti-RSV antibodies

Trellis Bioscience, Inc. announced today the granting of a worldwide exclusive license to MedImmune, LLC, the global biologics unit of AstraZeneca, to develop and commercialize Trellis’ antibodies directed against the respiratory syncytial virus (RSV).

1 Dec 2009

Bayer Schering Pharma to develop new BiTE antibody for treatment of solid tumors

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.

1 Dec 2009

MAbs for early detection of cancer

Two sets of recommendations issued earlier this month have revised longstanding guidelines concerning the age at which women should first be tested for breast and cervical cancer and how frequently.

1 Dec 2009

Portuguese scientists identify a molecular mechanism that can lead to metastases in breast cancers

Portuguese scientists identified a molecular mechanism that can lead to metastases (spread of the cancer from the original site to other remote parts of the body) in breast cancers. Abnormally high levels of P-cadherin - an adhesion molecule that enables cells to bind together - occur in about a third of all breast cancers and are associated with poor prognosis.

1 Dec 2009

Researchers devise a way to deliver right therapy directly to tumors using aptamers

Finding and treating a tumor without disturbing normal tissue presents challenges - sometimes the most effective therapies can be invasive and harsh.

1 Dec 2009

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -produced from healthy and tumour cells from the patient him or herself- and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

1 Dec 2009

Avioq receives premarket approval from FDA for Avioq HIV-1 Microelisa System

Avioq, Inc. announced it has received premarket approval from the U.S. Food and Drug Administration (FDA) for the Avioq HIV-1 Microelisa System.

1 Dec 2009

Aegis Therapeutics signs License Agreement with Roche

Aegis Therapeutics LLC (Aegis) announced today that they have signed a License Agreement providing Roche access to Aegis' proprietary ProTek® stabilization technology. The ProTek® technology covers the use of specific excipients as stabilizers in certain manufacturing processes and formulations of protein-based therapeutics.

1 Dec 2009

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

Novavax, Inc. announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal influenza VLP vaccine to a commercially available trivalent inactivated vaccine, TIV (Fluzone®).

30 Nov 2009

Xencor licenses its XmAb and Xtend technology platforms to Centocor Research & Development

Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. for the optimization of Centocor’s antibody drug candidates.

30 Nov 2009

Micromet to present new results from its blinatumomab study at the ASH meeting

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana.

30 Nov 2009

$Stem cell technology for rapid healing of complicated bone fractures$

Stem cell technology for rapid healing of complicated bone fractures

A novel technology involving use of stem cells, developed by Hebrew University of Jerusalem researchers, has been applied to provide better and rapid healing for patients suffering from complicated bone fractures.

30 Nov 2009

Agriflu approved to prevent diseases caused by influenza virus subtypes A and B

The U.S. Food and Drug Administration today approved Agriflu for people ages 18 years and older to prevent disease caused by influenza virus subtypes A and B.

27 Nov 2009

iCo Therapeutics reports financial results for three months ended September 30, 2009

iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

27 Nov 2009

B cells and their antibodies defend against microbes and control commensal microflora

Microbes populated the earth long before any eukariotic cell. Therefore, in order to survive, mono and multi-cellular organisms had to develop mechanisms of adaptation, cohabitation and defense against bacteria, fungi and viruses. One of these mechanisms is mediated by immunoglobulins in the serum and at mucosal surfaces.

27 Nov 2009

Antibody News and Research

Further Reading

Canadians with hemophilia A can use new treatment option, XYNTHA

MRI pioneer honored with MRC Millennium Medal

FDA grants approval for Dyax' KALBITOR for treating HAE patients

Missouri scientists discover aspirin and Tylenol can inhibit vaccine efficacy

MedImmune to develop and commercialize Trellis Bioscience's anti-RSV antibodies

Bayer Schering Pharma to develop new BiTE antibody for treatment of solid tumors

MAbs for early detection of cancer

Portuguese scientists identify a molecular mechanism that can lead to metastases in breast cancers

Researchers devise a way to deliver right therapy directly to tumors using aptamers

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

Avioq receives premarket approval from FDA for Avioq HIV-1 Microelisa System

Aegis Therapeutics signs License Agreement with Roche

Clinical trials of personalised vaccines to fight glioblastomas

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

Xencor licenses its XmAb and Xtend technology platforms to Centocor Research & Development

Micromet to present new results from its blinatumomab study at the ASH meeting

Stem cell technology for rapid healing of complicated bone fractures

Agriflu approved to prevent diseases caused by influenza virus subtypes A and B

iCo Therapeutics reports financial results for three months ended September 30, 2009

B cells and their antibodies defend against microbes and control commensal microflora

Using single B cell screening to boost antibody discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News